EUVIMEDEUVIMED entdecken
Scoping Review

Pharmacological management of transthyretin amyloid cardiomyopathy: a scoping review

Shafi Rehman, Shameera Shaik Masthan, Ramzi Ibrahim iD, Hoang Nhat Pham, Danial Hassan, Fahad Ahmad, Mohammad Shahzad Asif, Ahmad Safdar, Zain Anwar, Shahzad Raza, Preethi William

European Heart Journal - Cardiovascular Pharmacotherapy · 2024

DOI: 10.1093/ehjcvp/pvae044 ↗

Kurz gefasst

Scoping Review in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2024. Verfasst von Shafi Rehman und 10 weiteren Autor:innen. Beteiligte Einrichtung: D epartment of Histopathology, Khyber Medical University, Road No. 2, University of Rd No. 2, Rahat Abad, Peshawar, Khyber Pakhtunkhwa 25120, Pakista…. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Transthyretin amyloid cardiomyopathy (ATTR-CM) is characterized by the accumulation of transthyretin (TTR) protein in the myocardium. The aim of this scoping review is to provide a descriptive summary of the clinical trials and observational studies that evaluated the clinical efficacy and safety of various agents used in ATTR-CM, with a goal of identifying the contemporary gaps in literature and to reveal future research opportunities. Methods and results The search was performed in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A literature search using several databases for observational and clinical trials investigating the treatment modalities for ATTR-CM was undertaken. We extracted data including study characteristics, primary endpoints, and adverse events from each study. A total of 19 studies were included in our scoping review. Out of which, 8 were clinical trials and 11 were observational analyses. The drugs evaluated included tafamadis, acoramidis, revusiran, doxycycline and tauroursodeoxycholic acid and doxycycline, diflusinil, inotersan, eplontersen, and patisiran. Tafamidis has shown to be efficacious in the management of ATTR-CM, particularly when initiated at earlier stages. RNA interference and antisense oligonucleotide drugs have shown promising impacts on quality of life. Additionally, this review identified gaps in the literature, particularly among long-term outcomes, comparative effectiveness, and the translation of research into economic contexts.

Conclusion

Multiple pharmacological options are potential disease-modifying therapies for ATTR-CM. However, many gaps exist in the understanding of these various drug therapies, warranting further research. The future directions for management of ATTR-CM are promising in regard to improving prognostic implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialCardiomyopathiesHumansCardiovascular AgentsObservational Studies as TopicPrealbuminTreatment Outcome

Stichwörter der Autor:innen

AmyloidCardiomyopathyInfiltrativeTransthyretin

Substanzen

Cardiovascular AgentsPrealbuminTTR protein, human

Autor:innen und Institutionen

  • D epartment of Histopathology, Khyber Medical University, Road No. 2, University of Rd No. 2, Rahat Abad, Peshawar, Khyber Pakhtunkhwa 25120, Pakistan.
  • Seattle Medical Post-Acute Care, 555 16th Ave, Seattle, WA 98122, USA.
  • Department of Medicine, University of Arizona-Banner University Medical Center, 1625 N Campbell Ave, Tucson, AZ 85719, USA.
  • Harvard TH Chan School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA.
  • Sindh Institute of Urology and Transplantation, Chand Bibi Rd, Ranchore Lane, Karachi, Karachi City, Sindh, Pakistan.
  • Department of Medicine, University College of Medicine and Dentistry, Lahore, Punjab, Pakistan.

ORCID-Profile: Ramzi Ibrahim

Zitieren

APA

Rehman, S., Masthan, S. S., Ibrahim, R., Pham, H. N., Hassan, D., Ahmad, F., Asif, M. S., Safdar, A., Anwar, Z., Raza, S., & William, P. (2024). Pharmacological management of transthyretin amyloid cardiomyopathy: a scoping review. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae044

Vancouver

Rehman S, Masthan SS, Ibrahim R, Pham HN, Hassan D, Ahmad F, et al. Pharmacological management of transthyretin amyloid cardiomyopathy: a scoping review. European Heart Journal - Cardiovascular Pharmacotherapy. 2024. doi:10.1093/ehjcvp/pvae044

BibTeX
@article{Rehman2024,
  author = {Rehman, Shafi and Masthan, Shameera Shaik and Ibrahim, Ramzi and Pham, Hoang Nhat and Hassan, Danial and Ahmad, Fahad and Asif, Mohammad Shahzad and Safdar, Ahmad and Anwar, Zain and Raza, Shahzad and William, Preethi},
  title = {Pharmacological management of transthyretin amyloid cardiomyopathy: a scoping review},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2024},
  doi = {10.1093/ehjcvp/pvae044}
}
Kostenlos starten →